THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 81 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $1,000 | -50.0% | 57 | 0.0% | 0.00% | – |
| Q3 2018 | $2,000 | +100.0% | 57 | 0.0% | 0.00% | – |
| Q2 2018 | $1,000 | -50.0% | 57 | 0.0% | 0.00% | – |
| Q1 2018 | $2,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q4 2017 | $2,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q3 2017 | $2,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q2 2017 | $2,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q1 2017 | $2,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q4 2016 | $2,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q3 2016 | $2,000 | +100.0% | 57 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | 0.0% | 57 | 0.0% | 0.00% | – |
| Q4 2015 | $1,000 | – | 57 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,134,718 | $23,160,000 | 2.47% |
| Baupost Group | 8,735,168 | $178,285,000 | 1.42% |
| Orbimed Advisors | 6,219,110 | $126,932,000 | 1.19% |
| CM Management, LLC | 50,000 | $1,021,000 | 0.76% |
| Tekla Capital Management LLC | 456,296 | $9,313,000 | 0.32% |
| Rock Springs Capital Management LP | 682,600 | $13,932,000 | 0.30% |
| Virtus ETF Advisers LLC | 32,871 | $671,000 | 0.28% |
| Cormorant Asset Management, LP | 550,000 | $11,226,000 | 0.25% |
| DAFNA Capital Management LLC | 41,165 | $840,000 | 0.20% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 484,206 | $9,883,000 | 0.18% |